GERN · Geron Corporation Common Stock
View on chartInsiders & Stakes
| Robert J. Spiegel Director | ▲ Buy | Grant | 212,161 Shares held | 9/30/2026 | View profile |
| Molineaux Susan Director | ▲ Buy | Grant | 130,527 Shares held | 12/29/2023 | View profile |
| Karin Eastham Director | ▲ Buy | Option Exercise | 109,047 Shares held | 1/13/2023 | View profile |
| James Ziegler EVP, Chief Commercial Officer | ▲ Buy | Open Market | 100,000 Shares held | 2/27/2025 | View profile |
| Bloom Olivia Kyusuk Director | ▼ Sell | Open Market | 74,588 Shares held | 2/8/2023 | View profile |
| Scott Alan Samuels EVP, Chief Legal Officer | ▲ Buy | Open Market | 26,682 Shares held | 2/27/2025 | View profile |
| Elizabeth G. O'Farrell Director | ▲ Buy | Open Market | 26,220 Shares held | 8/24/2023 | View profile |
| Michelle Robertson Director | ▼ Sell | Open Market | 17,645 Shares held | 2/18/2026 | View profile |
| V. Bryan Lawlis Director | ▲ Buy | Open Market | 13,300 Shares held | 5/9/2025 | View profile |
| John A. Scarlett Chairman, President and CEO | ▲ Buy | Open Market | 12,500 Shares held | 2/27/2025 | View profile |
| Aggarwal Gaurav Director | ▲ Buy | Grant | 1,970 Shares held | 12/29/2023 | View profile |
| Andrew J. Grethlein EVP, Chief Operating Officer | ▼ Sell | Open Market | 0 Shares held | 7/8/2024 | View profile |
| Anil Kapur Director | ▼ Sell | Open Market | 0 Shares held | 6/10/2024 | View profile |
| Feller Faye EVP, Chief Medical Officer | ▼ Sell | Open Market | 0 Shares held | 6/10/2024 | View profile |
Transaction History
| Robert J. Spiegel | ▲ Buy | Grant | 6,351 | $8K | 9/30/2026 |
| Robert J. Spiegel | ▲ Buy | Grant | 6,103 | $8K | 6/30/2026 |
| Robert J. Spiegel | ▲ Buy | Grant | 5,243 | $8K | 3/31/2026 |
| Michelle Robertson | ▲ Buy | Option Exercise | 27,500 | $0 | 2/18/2026 |
| Michelle Robertson | ▼ Sell | Open Market | 9,855 | $19K | 2/18/2026 |
| Robert J. Spiegel | ▲ Buy | Grant | 5,918 | $8K | 12/31/2025 |
| Robert J. Spiegel | ▲ Buy | Grant | 5,702 | $8K | 9/30/2025 |
| Robert J. Spiegel | ▲ Buy | Grant | 5,540 | $8K | 6/30/2025 |
| V. Bryan Lawlis | ▲ Buy | Open Market | 13,300 | $16K | 5/9/2025 |
| Robert J. Spiegel | ▲ Buy | Grant | 4,913 | $8K | 3/31/2025 |
| John A. Scarlett | ▲ Buy | Open Market | 12,500 | $22K | 2/27/2025 |
| Scott Alan Samuels | ▲ Buy | Open Market | 15,000 | $24K | 2/27/2025 |
| James Ziegler | ▲ Buy | Open Market | 100,000 | $160K | 2/27/2025 |
| Robert J. Spiegel | ▲ Buy | Grant | 2,206 | $0 | 12/31/2024 |
| Robert J. Spiegel | ▲ Buy | Grant | 1,767 | $0 | 9/30/2024 |
| Andrew J. Grethlein | ▲ Buy | Option Exercise | 674,348 | $1.2M | 7/8/2024 |
| Andrew J. Grethlein | ▼ Sell | Open Market | 674,348 | $3.1M | 7/8/2024 |
| Robert J. Spiegel | ▲ Buy | Grant | 1,916 | $0 | 6/28/2024 |
| Feller Faye | ▲ Buy | Option Exercise | 112,500 | $119K | 6/10/2024 |
| Feller Faye | ▲ Buy | Option Exercise | 20,000 | $21K | 6/10/2024 |
| Feller Faye | ▲ Buy | Option Exercise | 155,400 | $201K | 6/10/2024 |
| Feller Faye | ▼ Sell | Open Market | 287,900 | $1.3M | 6/10/2024 |
| Anil Kapur | ▲ Buy | Option Exercise | 421,875 | $447K | 6/10/2024 |
| Anil Kapur | ▼ Sell | Open Market | 421,875 | $2.0M | 6/10/2024 |
| John A. Scarlett | ▲ Buy | Option Exercise | 600,000 | $1.5M | 6/4/2024 |
| John A. Scarlett | ▼ Sell | Open Market | 600,000 | $2.4M | 6/4/2024 |
| V. Bryan Lawlis | ▲ Buy | Option Exercise | 35,000 | $68K | 5/15/2024 |
| V. Bryan Lawlis | ▼ Sell | Open Market | 35,000 | $131K | 5/15/2024 |
| Robert J. Spiegel | ▲ Buy | Grant | 2,462 | $0 | 3/29/2024 |
| Aggarwal Gaurav | ▲ Buy | Grant | 1,970 | $0 | 12/29/2023 |
| Robert J. Spiegel | ▲ Buy | Grant | 3,406 | $0 | 12/29/2023 |
| Molineaux Susan | ▲ Buy | Grant | 6,220 | $0 | 12/29/2023 |
| Robert J. Spiegel | ▲ Buy | Grant | 3,390 | $0 | 9/29/2023 |
| Molineaux Susan | ▲ Buy | Grant | 6,191 | $0 | 9/29/2023 |
| Elizabeth G. O'Farrell | ▲ Buy | Open Market | 6,607 | $15K | 8/24/2023 |
| Elizabeth G. O'Farrell | ▲ Buy | Open Market | 6,579 | $15K | 8/24/2023 |
| Molineaux Susan | ▲ Buy | Grant | 4,088 | $0 | 6/30/2023 |
| Robert J. Spiegel | ▲ Buy | Grant | 2,239 | $0 | 6/30/2023 |
| Anil Kapur | ▲ Buy | Grant | 7,567 | $15K | 6/30/2023 |
| V. Bryan Lawlis | ▲ Buy | Option Exercise | 35,000 | $39K | 5/11/2023 |
| V. Bryan Lawlis | ▼ Sell | Open Market | 35,000 | $105K | 5/11/2023 |
| Molineaux Susan | ▲ Buy | Option Exercise | 35,000 | $39K | 5/1/2023 |
| Molineaux Susan | ▼ Sell | Open Market | 35,000 | $87K | 5/1/2023 |
| Robert J. Spiegel | ▲ Buy | Grant | 3,312 | $0 | 3/31/2023 |
| Molineaux Susan | ▲ Buy | Grant | 6,048 | $0 | 3/31/2023 |
| John A. Scarlett | ▲ Buy | Option Exercise | 446,668 | $670K | 2/10/2023 |
| John A. Scarlett | ▼ Sell | Open Market | 446,668 | $1.3M | 2/10/2023 |
| Andrew J. Grethlein | ▲ Buy | Option Exercise | 150,000 | $227K | 2/9/2023 |
| Andrew J. Grethlein | ▼ Sell | Open Market | 150,000 | $454K | 2/9/2023 |
| Andrew J. Grethlein | ▼ Sell | Open Market | 234,719 | $711K | 2/9/2023 |
| John A. Scarlett | ▲ Buy | Option Exercise | 446,666 | $670K | 2/9/2023 |
| John A. Scarlett | ▼ Sell | Open Market | 446,666 | $1.4M | 2/9/2023 |
| Bloom Olivia Kyusuk | ▲ Buy | Option Exercise | 400,000 | $604K | 2/8/2023 |
| Bloom Olivia Kyusuk | ▼ Sell | Open Market | 400,000 | $1.2M | 2/8/2023 |
| John A. Scarlett | ▲ Buy | Option Exercise | 446,666 | $670K | 2/8/2023 |
| John A. Scarlett | ▼ Sell | Open Market | 446,666 | $1.4M | 2/8/2023 |
| Karin Eastham | ▲ Buy | Option Exercise | 35,000 | $39K | 1/13/2023 |
| Anil Kapur | ▲ Buy | Grant | 6,021 | $7K | 12/30/2022 |
| Robert J. Spiegel | ▲ Buy | Grant | 2,970 | $0 | 12/30/2022 |
| Robert J. Spiegel | ▲ Buy | Grant | 3,071 | $0 | 9/30/2022 |
| Andrew J. Grethlein | ▲ Buy | Option Exercise | 2,000 | $3K | 9/12/2022 |
| Andrew J. Grethlein | ▲ Buy | Option Exercise | 232,719 | $396K | 9/12/2022 |
| Anil Kapur | ▲ Buy | Grant | 13,062 | $14K | 6/30/2022 |
| Robert J. Spiegel | ▲ Buy | Grant | 4,637 | $0 | 6/30/2022 |
| Karin Eastham | ▲ Buy | Option Exercise | 35,000 | $49K | 4/20/2022 |
| Robert J. Spiegel | ▲ Buy | Grant | 5,284 | $0 | 3/31/2022 |
| Robert J. Spiegel | ▲ Buy | Grant | 5,891 | $0 | 12/31/2021 |
| Robert J. Spiegel | ▲ Buy | Grant | 5,246 | $0 | 9/30/2021 |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 16, 2026
GERN Highlights Imetelstat at International Hematology Congresses
Geron Corporation announced that it will give oral presentations on its drug Imetelstat at international hematology congresses in Europe and Asia. The presentations are part of the company’s effort to advance Imetelstat’s clinical development and share results with the medical community. The news comes as the stock trades near its 52‑week low and around a $1.40 support level, with recent signals indicating a revenue‑price divergence.
GERN Highlights Imetelstat at International Hematology Congresses. Geron Corporation announced that it will give oral presentations on its drug Imetelstat at international hematology congresses in Europe and Asia. The presentations are part of the company’s effort to advance Imetelstat’s clinical development and share results with the medical community. The news comes as the stock trades near its 52‑week low and around a $1.40 support level, with recent signals indicating a revenue‑price divergence.